Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ARBs versus ACE inhibitors: lower all-cause mortality
Comparative · ACEARB-COMP-01 · v2
Several real-world studies that compared people taking ARBs with people taking ACE inhibitors found fewer deaths among the ARB users, and these came from different countries and patient groups [3][10][15][12][9][14]. But the picture is not consistent: one large, carefully matched study of heart-attack patients found the opposite, with noticeably more deaths among ARB users [5]. The biggest apparent advantages came from the smallest studies, while the largest studies showed only slight differences, which is a pattern that can appear by chance or bias rather than a true effect. When patients were actually randomly assigned to one drug or the other in head-to-head trials, the two drugs performed the same [1][2], suggesting the real-world death gap may reflect which patients were chosen for each drug rather than the drug itself. The panel therefore treated the association as present in the observational record but modest and unreliable.
Six independent observational head-to-head cohorts report lower all-cause mortality with ARBs than ACEi, spanning high cardiovascular risk [3] (HR 0.89), post-myocardial-infarction [10] (aHR 0.82), heart failure with non-reduced ejection fraction [15] (aHR 0.74), MASLD [14] (HR 0.94), and trial-emulation populations [9] (RR 0.36) and [12] (HR 0.56). Against this, a large propensity-matched cohort of hypertensive AMI patients reports the opposite, with all-cause death markedly higher on ARBs [5] (HR 1.81). Composite-endpoint cohorts favour ACEi, including a target-trial emulation [7] (4-point MACE HR 0.83) and a renal-impairment AMI cohort [13] (MACCE HR 1.34). The two head-to-head randomised trials in the corpus show class equivalence on hard outcomes [1] (RR 1.01) and [2] (HR 1.00). The contested point: The division is whether the ARB-favourable observational signal reflects a real survival difference or confounded prescribing. The directly on-point contradiction in [5], the reversal in composite-endpoint cohorts [7][13], and the disappearance of any advantage under randomisation [1][2] all pull against a true drug effect, while [3][10][15][12][9][14] sustain the association.
All 31 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
A large propensity-matched observational cohort [5] directly contradicts the claim, reporting ARB associated with 81% higher all-cause death (HR 1.81, 1.44-2.28) in hypertensive AMI patients. This is the same design, outcome and comparator as the supporting studies, so the directional claim cannot be stated as a settled observational finding.
Confounding by indication/channelling. Head-to-head RCTs [1] (ONTARGET, composite RR 1.01) and [2] (VALIANT, all-cause death HR 1.00) show class equivalence; where randomisation removes selective prescribing the ARB mortality advantage vanishes, implying the observational signal reflects ARBs being given to healthier or ACEi-intolerant patients rather than a true survival effect.
Where it remains uncertain. A large propensity-matched cohort shows the opposite (HR 1.81) [5], and randomised head-to-head trials show equivalence [1][2], implying the observational advantage may reflect selective prescribing rather than a drug effect.
Aleatory
The largest effects [9] RR 0.36 and [12] HR 0.56 rest on hundreds of users with very wide confidence intervals, so random variation alone could account for much of the apparent advantage.
Epistemic
Observational ARB vs ACEi comparisons [3][10][14][15] cannot rule out that ARBs were preferentially given to healthier or ACEi-intolerant patients; randomised head-to-head trials [1][2] show equivalence.
Inferential
Several contradicting cohorts [4][7][13] report MACE or MACCE rather than isolated all-cause mortality, so their bearing on the exact all-cause-mortality wording is only partial.
The load-bearing papers from a corpus of 31, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large high-CV-risk registry (n=40,625) showing ARB associated with 11% lower all-cause mortality than ACEi
“Similar results were observed for CV (6.9% vs 8.2%; HR 0.83; 95% CI 0.75 to 0.93; p=0.001) and all-cause mortality (11.6% vs 12.6%; HR 0.89; 95% CI 0.82 to 0.97; p=0.005).”
Panel auditInternal validity: medium · scope of inference: High cardiovascular-risk patients in real-world practice; benefit noted mainly in secondary prevention.Key limitations: observational confounding by indication · interaction: benefit only in secondary prevention
Large matched AMI cohort (n=29,986) supporting ARB all-cause mortality advantage
“Patients who received ARBs had significantly lower all-cause mortality (adjusted hazard ratio [aHR]: 0.82; 95% confidence interval [CI]: 0.75-0.90) and hospitalization for heart failure (aHR: 0.92; 95% CI: 0.85-0.99) compared with those who received ACEIs at 18 month follow-up.”
Panel auditInternal validity: medium · scope of inference: Taiwanese patients hospitalized with acute MI, 2002-2015.Key limitations: observational confounding · AMI population only · 18-month follow-up
Target-trial emulation supporting lower death with ARB; small subcohort, wide CI
“There were no appreciable differences in pooled analyses, except that ARBs versus ACEIs were associated with a lower death rate (HR, 0.56 [95% CI, 0.37-0.85]).”
Panel auditInternal validity: medium · scope of inference: ACCORD-BP and SPRINT participants (diabetes / high cardiovascular risk).Key limitations: death a secondary endpoint · primary CVD outcome null · small ARB counts
Directly contradicting observational cohort: ARB associated with substantially HIGHER all-cause death
“After propensity score-matching, ARB therapy was still associated with higher incidence of 2-year cardiac death (hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.20-2.14; P = 0.001), all-cause death (HR, 1.81; 95% CI, 1.44-2.28; P < 0.001), and MI (HR, 1.76; 95% CI, 1.25-2.46; P = 0.001) than the ACEI therapy.”
Panel auditInternal validity: medium · scope of inference: Hypertensive patients with acute MI in South Korea.Key limitations: observational confounding · specific hypertensive AMI subpopulation
4 of 31 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The observational literature leans toward an ARB all-cause-mortality advantage but with a directly contradicting large cohort, population-dependent reversals, and small-study inflation, placing the claim in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Direct contradiction in matched AMI cohorts. [5] reports ARB-associated higher all-cause death in hypertensive AMI while [10] reports lower death post-AMI, in the same design class, so the observational direction is unsettled where it is best studied. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A harmonised multi-database observational study restricted to AMI populations using a common active-comparator new-user protocol and all-cause mortality as the primary endpoint.
Open question: Does the ARB all-cause-mortality advantage persist in AMI populations once a uniform active-comparator design is applied across databases? Why it is still open: [5] and [10] report opposite directions in similar AMI cohorts.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19